Contributed Poster Presentations

All contributed poster presentations are available for viewing on Thursday, May 28 and Friday, May 29

Poster Topics

"ECONOMIC AND OUTCOMES ISSUES IN CARDIOVASCULAR DISEASE" FACTORS INFLUENCING THE DECISION TO TREAT SERUM LIPID DISORDERS BY DRUG THERAPY IN THE PRIMARY CARE VENUE Yuan Y, Silbert G, Doyle J, Copeland K. IMS America, Plymouth Meeting, PA, USA AN ANALYSIS OF THE ECONOMICS OF HYPERTENSION West DS1, Corey R2. 1University of Mississippi, Oxford, MS, USA, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA HOW DOES GENDER AFFECT PHARMACOTHERAPY TREATMENT DECISIONS FOR HYPERCHOLESTEROLEMIA/HYPERLIPIDEMIA Copeland K, Yuan Y. IMS America, Plymouth Meeting, PA, USA EMPIRICAL ANALYSIS OF THE COST-EFFICIENCY OF HMG-CoA REDUCTASE INHIBITORS Foley J.L. Churchill Health Economics, Secaucus, NJ, USA PHARMACEUTICAL COSTS OF PATIENT NON-ADHERENCE TO LIPID-LOWERING DRUG THERAPY Beck P1, Downey W1, Butler-Jones D1, L Lueck2, 1Saskatchewan Health, Regina, Canada, 2GDS & Associates, Regina, Canada DEVELOPMENT OF A DECISION-ANALYTIC MODEL OF STROKE CARE IN US AND EUROPE Chambers M1, Koch P2, Hutton J1, 1MEDTAP International Inc., London UK 2Boehringer Ingelheim GmbH, Ingelheim, Germany ECONOMIC EVALUATION OF TORASIMIDE IN CONGESTIVE HEART FAILURE IN GERMANY Spannheimer A1, Goertz A2 1Kendle/gmi, Munich, Germany; 2Boehringer Mannheim, Mannheim, Germany READINESS TO COMPLY AND OUTCOMES OF ANTIHYPERTENSIVE THERAPY Garfield FB1, Willey C2, Stafford J3, Redding C2, Caro JJ1. 1Caro Research, Boston, MA, USA, 2University of Rhode Island, Kingston, RI, USA, 3Bristol-Myers Squibb/Sanofi Pharma, Princeton, NJ, USA STUDY OF HYPERTENSIVE PRESCRIBING PRACTICES Schulman KA1, Mehta SS1, Gersh BJ2, Schneider EC3, Wilcox C4, 1Clinical Economics Research Unit,2Division of Cardiology, 3Institute for Health Care Research and Policy, 4Division of Nephrology and Hypertension at Georgetown University Medical Center, Washington, DC, USA MEDICAL AND ECONOMIC OUTCOMES IN PATIENTS TREATED WITH DILTIAZEM OR DIGOXIN FOR ATRIAL FIBRILLATION: A DATA BASE ANALYSIS Windisch PA, Vlasses PH, Jankowski L, University HealthSystem Consortium, Oak Brook, IL, USA THE IMPACT OF UNSTABLE ANGINA ON THE USE OF MEDICAL RESOURCES IN ITALY Maggioni AP, Schweiger C, Tavazzi L on behalf of the EARISA Investigators. ANMCO Research Center, Florence, Italy ONE-YEAR CLINICAL AND ECONOMIC OUTCOMES OF PRIMARY CORONARY ANGIOPLASTY USING A NATIONAL DATABASE. Akhras KS, Lowe LP, Arguelles LM. G. D. Searle & Co. Chicago, IL, USA PREVALENCE AND COST OF HOSPITALIZATIONS DUE TO ANGINA IN THE UNITED STATES USING A NATIONAL DATABASE Akhras KS, Zhao SZ, G.D. Searle & Co, Chicago, IL, USA NONPARAMETRIC ANALYSIS OF COST EFFECTIVENESS RATIOS OF PRAVASTATIN IN PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE Yuan Y1, Hay J1, LaPuerta P2, Leahy M3, University of Southern California 2Bristol-Myers Squibb Co., Princeton, NJ, USA, 3Pharmecon International, LLC., Old Lyme, CT, USA STUDY OF PROCEDURE COSTS AND OUTCOMES ASSOCIATED WITH THE PHARMACOLOGICAL TREATMENT OF ARTERIAL DISEASE AND INTERMITTANT CLAUDICATION IN THE DEPARTMENT OF DEFENSE Zachry W, Wilson J, Lawson K, Koeller J, The University of Texas at Austin, Austin, TX, USA SMOKING RELATED COSTS IN THE UNITED STATES Chua WQ1, Young TL2, Lloyd KB2, Sullivan SD1, 1University of Washington Department of Pharmacy, Seattle, WA, USA, 2Glaxo Wellcome Inc., Research Triangle Park, NC, USA LIPID THERAPY AND CARDIOVASCULAR DISEASE: HOW MANY AMERICANS SHOULD BE TREATED? Yu WM1, Hay JW2, 1University of Pittsburgh, School of Pharmacy, Pittsburgh, PA, USA, 2University of Southern California, School of Pharmacy, Los Angeles, CA, USA THE IMPACT OF ACUTE RENAL FAILURE ON COST IN ELDERLY PATIENTS WITH CONGESTIVE HEART FAILURE Chen Y-T1, Bradford D1, Wang Y2, Seltzer J1, Krumholz H1, 1Yale University School of Medicine, New Haven, CT, USA; 2Connecticut Peer Review Organization, Middletown, CT, USA EVALUATION OF THE COSTS OF HEART FAILURE IN BELGIUM Annemans L1,2, Block P2, Van Rompay W1, Closon MC3, 1HEDM, Belgium; 2Vrije Universiteit Brussel, Belgium, 3Université Catolique Louvain, Belgium CONVENIENCE IMPLICATIONS OF A SINGLE BOLUS THROMBOLYTIC Banks JL1, Garfield FB1, LaPuerta P2, Spencer-Green G1, Caro JJ1, 1Caro Research, Boston, MA, USA, 2Bristol-Myers Squibb, Princeton, NJ, USA COST CONSEQUENCES OF ACUTE MYOCARDIAL INFARCTION IN DIABETIC PATIENTS THE FIRST YEAR O'Brien JA, Shomphe LA, Kavanagh PL, Caro JJ, Caro Research, Boston, MA, USA "ECONOMIC AND OUTCOMES ISSUES IN GI DISORDERS, DIABETES, ASTHMA, AND OTHER DISORDERS" THE EFFECTS OF COMMUNITY-BASED PHARMACEUTICAL CARE SERVICES ON ASTHMA-RELATED QUALITY OF LIFE Boyd BJ, Rascati, KL, Lawson, KA, The University of Texas at Austin College of Pharmacy, Austin, TX, USA THE ECONOMIC IMPLICATIONS OF DECREASED PATIENT ADHERENCE TO CO-PRESCRIBED DICLOFENAC AND MISOPROSTOL (CoRx-D&M) RELATIVE TO A SINGLE-TABLET FORMULATION OF DICLOFENAC/MISOPROSTOL (STF-D/M). Goldstein JL1, Stewart D2, Zabinski RA3, Larson LR4, 1University of Illinois Chicago,IL,USA; 2Brogan Inc, Toronto,Canada, 3GD Searle, & Co, Skokie, IL, USA, 4ClinTrial Ovation, Highland PArk, IL, USA COST-UTILITY-RELATION OF THE TREATMENT OF DIABETIC FOOT LESION WITH HYPERBARIC OXYGENE THERAPY VERSUS STANDARD THERAPY Kilburg A., Rychlik R., Rappenhöner B., Institute of Empirical Health Economics, Odenthal, Germany COST EFFECTIVENESS ANALYSIS OF SCREENING OF TYPE II DIABETES MELLITUS IN NONPREGNANT ADULTS Hui RL, Hay JW, School of Pharmacy, University of Southern California, Los Angeles, CA, USA PREDICTING HOSPITALIZATION OF PATIENTS WITH DIABETES MELLITUS: AN APPLICATION OF THE BAYESIAN DISCRIMINANT ANALYSIS Bhattacharyya S, Procter & Gamble Pharmaceuticals, Cincinnati, OH, USA A MANAGED CARE COST ANALYSIS OF THE TREATMENT OF PSORIASIS Patterson HK, and Gillis SM SmithKline Beecham Pharmaceuticals, Collegeville, PA, USA CONSEQUENCES OF HIGH HEMATOCRIT MAINTENANCE AMONG HEMODIALYSIS PATIENTS. Shih Y, Kauf TL, UNC School of Pharmacy, Chapel Hill, NC, USA COMPARISON OF PREVALENCE RATES OF LOW BACK DISORDERS OBTAINED FROM TWO LARGE NATIONAL CLAIMS DATABASES Dedhiya SD, Zhao SZ, Arguelles LM, G.D. Searle & Co., Skokie, IL., USA OUTCOMES AND COST-BENEFIT OF INHALED CORTICOSTEROID THERAPY INTRODUCTION IN MEDICAID ENROLLED ASTHMATIC CHILDREN Balkrishnan R, Norwood GJ, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA BAMBUTEROL IS A MORE COST-EFFECTIVE TREATMENT THAN SALMETEROL IN ASTHMA PATIENTS WITH NOCTURNAL SYMPTOMS Crompton GK1, Brusasco V2, Eivindson A3, Jamieson AH4, Olsson H5, Svensson K5, Ståhl E5. 1Western General Hospital, Edinburgh, UK, 2Ospedale S Martino, Genova, Italy, 3Aust-Agder Sentralsykehus, Arendal, Norway, 4Astra Clinical Research Unit, Edinburgh, UK, 5Astra Draco AB, Lund, Sweden VALIDITY AND RELIABILITY OF AN AMERICAN TRANSLATION OF THE ST. GEORGE'S RESPIRATORY QUESTIONNAIRE Barr JT, Schumacher GE, Freeman S, Collette K, and the PROAS Group, Northeastern University, and Massachusetts Association of Cardiovascular and Pulmonary Rehabilitation, Boston, MA, USA COST OF PRESCRIPTION DRUGS AND COST OF TREATMENT FAILURE FOR SINUSITIS Nadesan B, Cady PS, Force RW, Force WS, Culbertson VL, Dept. of Pharmacy Practice and Admin. Sciences, Idaho State University, Pocatello, ID, USA DOES THE DURATION OF PULMONARY REHABILITATION AFFECT THE MAGNITUDE OF PATIENT RESPONSE? Barr JT, Schumacher GE, Coleman AM, PROAS Group, Northeastern University, and Massachusetts Association of Cardiovascular and Pulmonary Rehabilitation, Boston, MA, USA A HEALTH ECONOMIC ANALYSIS OF FLUTICASONE PROPIONATE, BUDESONIDE, AND BECLOMETHASONE DIPROPIONATE FOR THE TREATMENT OF MODERATE TO SEVERE ASTHMA. Trakas K1, Oh PI1,2, Einarson TR1, Shear NH1,2. 1University of Toronto, Toronto, Canada; 2Sunnybrook Health Science Centre, Toronto, Canada. VETERANS' SATISFACTION WITH H2-RECEPTOR ANTAGONIST (H2RA) DRUG CONVERSION Lane K, Department of Veterans Affairs Medical Center, San Francisco, CA, USA "ECONOMIC AND OUTCOMES ISSUES IN HORMONE REPLACEMENT THERAPY, ARTHRITIS, AND OSTEOPOROSIS" EFFICIENT STRATEGIES FOR OSTEOPOROSIS TESTING Abbott TA1, Mucha LM1, Manfredonia D1, Schwartz E2, Berger M1, 1Merck & Co., Inc., West Point, PA, USA, 2Foundation for Osteoporosis Research & Education, Oakland, CA, USA SF-12 OSTEOARTHRITIS-SPECIFIC HEALTH INDEX: DEVELOPMENT AND VALIDATION Gandhi SK1, Salmon JW1, Zhao SZ2, Lambert BL1, Gore P1, Conrad K1. 1University of Illinois at Chicago, Chicago, IL.2G. D. Searle, Skokie, IL, USA PSYCHOMETRIC EVALUATION OF SF-12 IN OSTEOARTHRITIS CLINICAL TRIALS Gandhi SK1, Salmon JW1, Zhao SZ2, Lambert BL1, Gore P1, Conrad K1. 1University of Illinois at Chicago, Chicago, IL, USA, 2G. D. Searle, Skokie, IL, USA THE RESPONSIVENESS OF DISEASE SPECIFIC AND GENERIC HEALTH MEASURES TO CHANGES IN THE SEVERITY OF RHEUMATOID ARTHRITIS AND TO TREATMENT Kosinski M1, Ware JE1, Zhao S2, Dedhiya S2, 1The Health Assessment Lab, New England Medical Center, Boston, MA, USA; 2Searle, Skokie, IL, USA THE RESPONSIVENESS OF DISEASE SPECIFIC AND GENERIC HEALTH MEASURES TO CHANGES IN THE SEVERITY OF OSTEOARTHRITIS Zhao S1, Dedhiya S1, Kosinski M2, Ware JE2, 1Searle, Skokie, IL, USA; 2Health Assessment Lab, New England Medical Center, Boston, MA, USA HEALTH CARE USE IN WOMEN AGE 45 AND OLDER Hoerger TJ1, Eleazer KR1, Lindrooth RC1, West SL1, Ohsfeldt R2, 1Research Triangle Institute, Research Triangle Park, NC, USA; 2Eli Lilly and Company, Indianapolis, IN, USA THE DIRECT MEDICAL COST OF OSTEPOROTIC FRACTURES Martin BC, Kotzan JA, Reeves JH, College of Pharmacy, University of Georgia, Athens, GA, USA COST-EFFECTIVENESS OF HORMONE THERAPY VERSUS CALCIUM THERAPY: AN OSTEOPOROSIS MARKOV MODEL Keys PJ1, Touchette D2, 1Wayne State University College of Pharmacy and Allied Health Professions, Detroit, MI, USA; 2Detroit Medical Center Receiving Hospital, Detroit, MI, USA USE OF CENTRALIZED PHARMACY RECORDS IN A MANAGED CARE ORGANIZATION TO DETERMINE EFFECT OF EDUCATIONAL MATERIAL ON HORMONE REPLACEMENT THERAPY PATIENT COMPLIANCE Chen Y1, McDevitt J1, Wolke O2, Sidorov J2. 1MEDEX Clinical Trials Services, Ardmore, PA, USA, 2Penn State Geisinger Health System, Danville, PA, USA QUALITY OF LIFE AND PHARMACOECONOMIC ASPECTS OF HORMONE REPLACEMENT THERAPY IN POST-MENOPAUSAL WOMEN - A CANADIAN RANDOMIZED TRIAL Haider S1, Benhaddad A2, Rosner A.J3, Ryan N3, Hux M3, 1Abt Associates Clinical Trials, Cambridge, MI, 2Schering Canada Inc., Pointe-Claire, QC, and 3Innovus Research Inc., Burlington, Ontario, Canada. DETERMINING MINIMALLY IMPORTANT CHANGES (MIC) IN RHEUMATOID ARTHRITIS (RA) FUNCTIONAL STATUS. Bagchi I1, Gillis SM2, Watrous ML2; 1University of Iowa, Iowa City, IA, USA; 2SmithKline Beecham Pharmaceuticals, Collegeville, PA, USA. "ECONOMIC AND OUTCOMES ISSUES OF IMMUNE AND INFECTIONS DISEASES AND CANCER" MARKOV CHAIN ESTIMATION OF LIFE EXPECTANCY OF HIV-INFECTED PATIENTS: COMPARISON OF TWO TREATMENT ALTERNATIVES Bhattacharyya SK1, Langley PC2, Draugalis JR3, Cox ER4, 1Procter & Gamble Pharmaceuticals, Cincinnati, OH, USA; 2University of Colorado Health Sciences Center, Denver, CO, USA; 3The University of Arizona, Tucson, AZ, USA; 4The University of Arizona, Tucson, AZ, USA. SOCIO-ECONOMIC RELEVANCE OF INPATIENT TREATMENT OF INTRA-ABDOMINAL INFECTIONS WITH TAZOBACTAM / PIPERACILLIN 0,5 g / 4,0 g IN COMPARISON WITH IMIPENEM / CILASTATIN Bruchhausen Y, Rappenhöner B, Kremer B, Rychlik R, Institute of Empirical Health Economics, Odenthal, Germany COLORECTAL CANCER SCREENING: COST-EFFECTIVENESS ANALYSIS FROM AN ITALIAN VIEWPOINT Bona M, Fusillo M, Grossi E, Ethical Drugs Medical Department - BRACCO S.p.A., Milan, Italy COST-EFFECTIVENESS OF PIPERACILLIN-TAZOBACTAM VERSUS CEFTAZIDIME IN PATIENTS WITH FEBRILE NEUTROPENIA Domínguez-Gil A1, Pérez M1, Santos L1, Sanz A1, Rubio C2, 1Hospital Universitario de Salamanca, Salamanca, Spain, 2Unidad de Farmacoeconomía, Wyeth-Lederle, Madrid, Spain. COST-EFFECTIVENESS ANALYSIS OF PIPERACILLIN-TAZOBACTAM VERSUS IMIPENEM-CILASTATIN IN THE TREATMENT OF INTRA-ABDOMINAL INFECTIONS Domínguez-Gil A1, Rubio C2, 1Hospital Universitario de Salamanca, Salamanca, Spain. 2Unidad de Farmacoeconomía, Wyeth-Lederle, Madrid, Spain. USING A PNEUMONIA SPECIFIC SEVERITY OF ILLNESS MODEL IN ASSESSING VARIATION IN HOSPITAL LENGTH OFSTAY FOR COMMUNITY ACQUIRED PNEUMONIA PATIENTS Tan, H, Koeller, J. The University of Texas at Austin and Health Science Center in San Antonio, TX, USA EPOETIN ALFA ADMINSITERED TO ACADEMIC HEALTH CENTER DIALYSIS PATIENTS: COMPARISON TO HCFA BILLING RECORDS Chen C, Danekas L, Matuszewski K, Vlasses PH, University HealthSystem Consortium, Oak Brook, IL, USA CLINICAL & ECONOMIC BENEFITS OF AN INFECTIOUS DISEASE APPROVAL PROGRAM. Kinky DE, Fishman NO, Morgan AS, Gibson GA. University of Pennsylvania Medical Center, Philadelphia, PA, USA THE CLINICAL AND ECONOMIC BENEFIT OF AN INFECTIOUS APPROVAL PROGRAM Kinky DE, Hospital of the University of Pennsylvania, Philadelphia, PA, USA THE INFLUENCE OF CASE MIX BIAS ON COSTS OF HOSPITALISATION FOR LOWER RESPIRATORY TRACT INFECTION Peter Davey, McMahon AD, White G, Morris AM, MacDonald TM, MEMO, Dundee, Scotland, UK A HEALTH ECONOMIC EVALUATION OF PACLITAXEL AND CARBOPLATIN VERSUS VINORELBINE AND CISPLATIN COMBINATION CHEMOTHERAPY IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER Sinha N1, Hainsworth JD2, Einarson TR3, Doyle JJ1, Arikian SR1, Lappas PT1, 1Center for Health Outcomes and Economics, A Division of Bristol-Myers Squibb Company, East Brunswick, NJ, USA, 2Sarah Cannon Cancer Center, Nashville, TN, USA, 3University of Toronto, Toronto, Canada "METHODS, SURVEYS, DATA COLLECTION, AND USE, AND OTHER ISSUES" INFORMATION TECHNOLOGY IN A LARGE MULTI-SITE OUTCOMES STUDY Morlock R, Ward R, Nerenz D, Feng J, Sadlocha K, Henry Ford Health System, Detroit, MI, USA, Oceania Inc., Palo Alto, CA, USA. THE EFFECT OF THE LOUISIANA MEDICAID LOCK-IN ON PRESCRIPTION DRUG UTILIZATION AND EXPENDITURES Blake SG, Feldhaus JF, Hunter TS, Rappaport H, Holt G, Medon PJ, Northeast Louisiana University, School of Pharmacy, Monroe, LA, USA USE OF ADMINISTRATIVE DATA TO CREATE DISEASE-SPECIFIC DATASETS FOR USE IN HEALTH ECONOMIC STUDIES Beck P, Downey W, Osei W, Baker M, Saskatchewan Health, Regina, Canada OUTCOMES RESEARCH INTERESTS OF A COMMUNITY PHARMACIST RESEARCH NETWORK Wade WE, Spruill WJ, Taylor AT, Longe RL, College of Pharmacy, The University of Georgia, Athens, GA, USA PRESCRIPTION MEDICATION USE IN OLDER AMERICANS. Mehta SS, Rathore SS, Boyko WL, Schulman KA, Clinical Economics Research Unit, Department of Medicine, Georgetown University Medical Center, Washington, DC, USA. CHRONIC CARE COSTS OF NEW MEDICARE HMO ENROLLEES: IMPLICATIONS FOR DISEASE MANAGEMENT Grannemann TW, Boxford, MA, USA. THE VALUE OF MEDICINES: IS THERE ENOUGH ECONOMIC EVIDENCE? Constenla D, Munro V, Hutton J, MEDTAP International Inc., London, UK PRENATAL CARE AND BIRTH WEIGHT IN THE UNITED STATES Weiwei F, Merck-Medco Managed Care, L.L.C., Montvale, NJ, USA. EVALUATION OF A PATHWAY FOR PROVIDING PHARMACEUTICAL CARE Burgess S, Perri M, Department of Clinical and Administrative Sciences, University of Georgia, Athens, GA, USA THE DEVELOPMENT OF A PATIENT OUTCOMES SOFTWARE FOR UROLOGISTS: CaPSURE POS®. Flanders S1, Henning JM1, Roth J2, Stier DM2, Grossfeld GD3, Carroll PR3, 1TAP Holdings Inc., Deerfield, IL, USA; 2Technology Assessment Group, San Francisco, CA, USA, 3UCSF, Department of Urology, San Francisco, CA, USA. USE OF ADMINISTRATIVE DATABASES IN SASKATCHEWAN, CANADA FOR PHARMACOECONOMIC AND OUTCOMES RESEARCH Downey W, Stang MR, Saskatchewan Health, Regina, Saskatchewan, Canada THE PARADOX OF LEAGUE TABLES Caro JJ1, Klittich WS1, Jackson JD2, 1Caro Research, Boston, MA, USA, 2Bristol-Myers Squibb, Princeton, NJ, USA APPLICATION OF PHARMACOECONOMICS AND OUTCOMES RESEARCH IN FORMULARY DECISION-MAKING Sarpong DF, Xavier University, College of Pharmacy, New Orleans, LA, USA VOX POPULI: STATED PREFERENCES FOR PHARMACEUTICAL INNOVATIONS Bingham MF1, Johnson FR1, Bell L2, 1Triangle Economic Research, Durham, NC, USA, 2Independent Consultant AN UNBIASED METHOD OF PHARMACEUTICAL COST ANALYSIS Nichol G, Wells G, Pham B. University of Ottawa, Ottawa, Canada. IMPLICATION OF PREVENTING DISEASE ON LIFE YEARS GAINED (LYG) Caro JJ, Klittich WS, for the WOSCOPS Economic Analysis Committee, Caro Research, Boston, MA, USA SURVEILLANCE OF A NEW DRUG IN THE UNITED KINGDOM (U.K.) Hartz SC, West S, Bunten E, Medical Research International, Burlington, MA, US and London, England, UK. "ECONOMIC AND OUTCOMES ISSUES IN MENTAL HEALTH AND NEUROLOGIC DISORDERS" THE ECONOMIC BURDEN OF SCHIZOPHRENIA: ACUTE GENERAL HOSPITAL COST O'Brien JA, Shomphe LA, Pietrusewicz MJ, Caro JJ, Caro Research, Concord, MA, USA ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE DURING TREATMENT OF OPIATE DEPENDENCE USING THE SHORT FORM - 36 Raisch DW, Garnand DA, Jones MS, Sather MR, Huber A, Ling W, VA Clinical Research Pharmacy Coordinating Center, Albuquerque, NM, USA, the LA Addiction Treatment Research Center, Los Angeles, CA, USA EVALUATION OF HUMANISTIC OUTCOMES FOR PATIENTS ON SELECTIVE SEROTONIN REUPTAKE INHIBITORS Sansgiry SS1, Burgoyne DS1, Busby CJ2, RxAmerica LLC1, Salt Lake City, UT, USA; 2Eli Lilly and Company, Sandy, UT, USA QUALITY OF LIFE AND ADVERSE REACTIONS IN DEPRESSED PATIENTS RECEIVING ANTIDEPRESSANT DRUGS Taylor AT, Spruill WJ, Longe RL, Wade WE, Ahmed A. University of Georgia, Athens, GA, USA THE COST OF TREATING SCHIZOPHRENIA IN THE CALIFORNIA MEDICAID (MEDI-CAL) PROGRAM McCombs JS, Nichol MB, Department of Pharmaceutical Economics and Policy, School of Pharmacy, University of Southern California, Los Angeles, CA, USA ECONOMIC OUTCOMES OF ANTIDEPRESSANT USE IN A MANAGED CARE ORGANIZATION White TJ, Nichol MB, USC School of Pharmacy, Department of Pharmaceutical Economics and Policy, LA, CA, USA A GENERAL MODEL OF THE EFFECTS OF ALTERNATIVE SEDATIVE-HYPNOTIC AGENTS ON THE COSTS OF MOTOR VEHICLE ACCIDENTS Menzin J, Lang K, Friedman M, Boston Health Economics, Inc., Billerica, MA, USA DURATION OF CONTINUOUS THERAPY BETWEEN ATYPICAL AND TYPICAL ANTIPSYCHOTICS Li Z1, Hutchins DS1, Johnstone BM2, Tunis SL2, Coleman TR2, Gevirtz F1, 1PCS Health Systems Inc., Scottsdale, AZ, USA; 2Eli Lilly and Company, Indianapolis, IN, USA MONTH-TO-MONTH ADHERENCE WITH ANTIPSYCHOTIC PHARMACOTHERAPY: A COMPARISON BETWEEN ATYPICAL AND TYPICAL ANTIPSYCHOTICS Li Z1, Hutchins DS1, Johnstone BM2, Tunis SL2, Coleman TR2, Gevirtz F1, 1PCS Health Systems Inc., Scottsdale, AZ, USA; 2Eli Lilly and Company, Indianapolis, IN, USA SELECTIVE SEROTONIN REUPTAKE INHIBITOR UTILIZATION PATTERNS: CONSISTENCY ACROSS RESEARCH DESIGNS Hutchins DS1, Klein EG2, Signa WF1, Young CH1, Gregor KJ1, 1PCS Health Systems Inc., Scottsdale, AZ, USA; 2Eli Lilly and Company, Indianapolis, IN, USA UTILIZATION REVIEW OF SSRI THERAPY AT A MENTAL HEALTH MANAGED CARE ORGANIZATION. Conner TM, Rascati KL, Crawford KM. The University of Texas at Austin, Austin, TX, USA TEXAS MEDICATION ALGORITHM PROJECT: FEASIBILITY STUDY OF IMPLEMENTING MEDICATION ALGORITHMS IN THE PUBLIC MENTAL HEALTH SECTOR Crismon ML, Rush AJ, Toprac MG, Shon S, Biggs MM, Shores-Wilson K, Mason M. The University of Texas System and Texas Department of Mental Health and Mental Retardation, Austin, TX, USA DEVELOPING A TASK-BASED INSTRUMENT TO MEASURE MIGRAINE RELATED PRODUCTIVITY Lee TA1, Ramsey SD2,3, Neil NJ1, Patrick DL3, Klastorin TD4, Stergachis A1,3, and Sullivan SD1,3, University of Washington, Schools of 1Pharmacy, 2Medicine, 3Public Health and Community Medicine, 4Business Administration, Seattle, WA, USA SCHIZOPHRENIA MANAGEMENT: DOES MANAGED CARE INFLUENCE LENGTH OF STAY IN U.S. HOSPITALS? O'Brien JA, Pietrusewicz MJ, Pierce D, Caro JJ, Caro Research, Boston, MA, USA DEVELOPMENT OF A SELF-ADMINISTERED OUTCOME MEASURE FOR USE IN AN OUTPATIENT POPULATION OF INDIVIDUALS WITH SCHIZOPHRENIA Judith Barr, Schumacher GE, Mason EJ, Ohman SM, Hanson A, Northeastern University and Massachusetts Division of Medical Assistance. A HEALTH POLICY ANALYSIS OF PHARMACOTHERAPY FOR MAJOR DEPRESSIVE DISORDER IN EUROPE AND THE AMERICAS Arikian SR1, 2, Einarson TR3, Casciano JP1, Doyle JJ1, 2, 1The Analytica Group, Ltd., Scarsdale, NY, 2Columbia School of Public Health, New York, NY, USA 3Faculty of Pharmacy, The University of Toronto, Ontario, Canada UTILIZATION PATTERNS OF ANTIDEPRESSANT MEDICATIONS IN A PATIENT POPULATION SERVED BY A PRIMARY CARE MEDICAL GROUP Venturini F1, Sung, JCY1, Nichol MB1, Sellner JC2, 1University of Southern California, School of Pharmacy, Department of Pharmaceutical Economics & Policy, Los Angeles, CA, USA, 2Eli Lilly & Co., Indianapolis, IN, USA